BTK inhibitor (Redx)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameBTK inhibitor (Redx)
Drug Alias NameIrreversible BTK Inhibitor (Redx Oncology)REDX-05194
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsAutoimmune DiseasesDiabetic NephropathiesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRedx Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRedx Oncology Ltd
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesDiabetic NephropathiesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A